← Back to Search

Hormone Therapy

androgel for Hypogonadotrophic Hypogonadism

N/A
Waitlist Available
Led By Paresh Dandona
Research Sponsored by University at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

Study Summary

The purpose of this study is to examine the effects of testosterone deficiency in men with diabetes on atherogenesis, inflammation, cardiovascular Risk factors And adiposity .

Eligible Conditions
  • Hypogonadotrophic Hypogonadism

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Carotid Intima Media Thickness
Secondary outcome measures
Endothelial Function

Trial Design

3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: androgelExperimental Treatment1 Intervention
androgel
Group II: no treatmentActive Control1 Intervention
eugonadal comparison arm
Group III: placeboPlacebo Group1 Intervention
placebo gel
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Testosterone
FDA approved

Find a Location

Who is running the clinical trial?

Solvay PharmaceuticalsIndustry Sponsor
131 Previous Clinical Trials
37,307 Total Patients Enrolled
University at BuffaloLead Sponsor
132 Previous Clinical Trials
98,932 Total Patients Enrolled
Paresh DandonaPrincipal InvestigatorKaleida Health
1 Previous Clinical Trials
30 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
Paresh Dandona 2007. "Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00467987.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top